Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 919 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy MOST POPULAR FDA Approves Avapritinib for Advanced Systemic Mastocytosis June 17, 2021 From smouldering ash to a gleaming temple for cancer research: The... April 26, 2023 Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer January 18, 2022 More Than One in 10 Patients With Lung Cancer Do Not... March 17, 2021 Load more HOT NEWS PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... Carriers of a Germline Pathogenic Variant in CDKN2A are at a... “Your Stories” Podcast: Amplifying Patient Voices
